CIPLA

Focus on respiratory & specialty drugs

🟢 Key Recent Developments 1. Weak recent quarterly performance 📉 Profit declined sharply YoY in the latest quarter Reasons: Supply disruption in a key drug Higher operating costs 👉 Impact: Stock saw pressure after results Short-term sentiment turned cautious 2. US business slowdown North America segment under pressure due to: Pricing competition in generics Lower contribution from key products 👉 Important because US contributes significantly to margins 3. Strong India business 🇮🇳 Domestic formulations business continues double-digit growth Strong presence in: Respiratory segment Chronic therapies 👉 This is currently the main stability driver 4. Focus on respiratory & specialty drugs Cipla strengthening its core segment: Inhalers Respiratory therapies New launches expected in coming quarters